Back to news

Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026

Globe Newswire•18/11/2026•08:00 ET
0

Key Highlights

  • ➤Elraglusib achieved 77% tumor growth inhibition with twice-daily oral dosing in melanoma mice
  • ➤Once-daily oral elraglusib achieved 50% tumor growth inhibition as monotherapy
  • ➤Phase 1/2 trial planned for Q1 2027 in refractory metastatic melanoma
  • ➤Daily dosing increased cytotoxic T cells and natural killer cells while reducing immunosuppressive myeloid cells
  • ➤Higher elraglusib drug exposures produced greater antitumor activity in the preclinical model

Expert Statements

Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics

“These results reinforce our strategy to advance elraglusib as a daily oral therapy and expand its potential applications in oncology”

Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics

“The exposure-response findings provide valuable insights to inform our upcoming clinical development program, while the observed effects on the tumor immune microenvironment further support the potential of elraglusib as both a monotherapy and in combination with other cancer treatments.”

Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics

“We look forward to initiating our Phase 1/2 clinical trial in the first quarter of 2027, beginning with patients with refractory metastatic melanoma.”

Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics and presenting author

“These findings provide important new insights into the relationship between elraglusib exposure and antitumor activity”

Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics and presenting author

“In this aggressive melanoma model, we observed greater tumor growth inhibition with increased drug exposure, alongside favorable changes in immune cell populations within the tumor microenvironment.”

Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics and presenting author

“Together, these findings support further investigation of daily oral dosing as a strategy to sustain GSK-3 inhibition and potentially enhance the antitumor activity of elraglusib.”

* Daily oral elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposures * Treatment was associated with changes in the tumor immune microenvironment, characterized by increased cytotoxic T cells and natural killer cells and reduced immunosuppressive myeloid cells * Findings further reinforce initiation of Phase 1/2 clinical trial in Q1 2027 with daily dosing of elraglusib oral tablet CHICAGO and FORT WORTH, Texas, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, today announced new preclinical data demonstrating that daily oral administration of elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive melanoma model, with greater antitumor activity associated with increased drug exposure. The findings, presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) (link), also demonstrated changes in the tumor immune microenvironment consistent with enhanced antitumor immune activity, supporting the continued development of Elraglusib Oral Tablet in the upcoming Phase 1/2 clinical trial to be initiated in the first quarter of 2027.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in